Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Front Endocrinol (Lausanne). 2024 Apr 11;15:1386510. doi: 10.3389/fendo.2024.1386510. eCollection 2024.
In hypothyroid patients needing large doses of levothyroxine (L-T4) (>1.7-2 μg/kg/day) to reach euthyroidism, lactose intolerance (LI) needs to be excluded, owing to the high prevalence in the population. If LI is present, a lactose-free diet decreases the rate of L-T4 malabsorption. However, an increased requirement of L-T4 is described in patients with LI, which can be beneficially treated using lactose-free L-T4 formulation. The lactose-free liquid L-T4 formulation is able to circumvent LI malabsorption leading to the normalization of thyroid-stimulating hormone (TSH) in patients with subclinical hypothyroidism and long-term stable TSH levels.
在需要大剂量左甲状腺素(L-T4)(>1.7-2μg/kg/天)以达到甲状腺功能正常的甲状腺功能减退症患者中,由于人群中发病率较高,需要排除乳糖不耐受(LI)。如果存在 LI,无乳糖饮食可降低 L-T4 吸收不良的发生率。然而,LI 患者描述了 L-T4 的需求增加,使用无乳糖 L-T4 制剂可以对其进行有益的治疗。无乳糖液体 L-T4 制剂能够避免 LI 吸收不良,导致亚临床甲状腺功能减退症患者的促甲状腺激素(TSH)正常化和长期稳定的 TSH 水平。